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HIV infected patients receiving antiretroviral therapy
(ART) can develop avascular osteonecrosis, 45 times
greater than the general population. Avascular osteone-
crosis increased in the last few years in patients with
HIV infection. The most important mechanisms for
avascular osteonecrosis in HIV-infected patients are:
changes in bone metabolism, especially osteoporosis
correlated with protease inhibitors and coagulopathy
and antiphospholipid syndrome, frequently described in
HIV infection. Aim: to describe different mechanisms of
avascular osteonecrosis
We present two HIV-infected patients under antire-
troviral therapy who developed avascular osteonecrosis.
First patient, male, 38 year-old, with AIDS-C3, with
good immuno-virological outcome under AZT-3TC and
lopinavir/ritonavir, developed severe osteoporosis after 5
years of ART, diagnosed by DXA test with a T-score
<-2,5. The patient had: C4-C5-C6 severe osteoporosis
with high fracture risk, with segmental instrumentation
applied at those levels, and then bilateral avascular
necrosis of femoral head (ANFH) with bilateral hip
arthroplasty. ART regimen was changed and the patient
received 3TC-ABC and Nevirapine. The patient didn’t
have other risk factors for avascular osteonecrosis or
osteoporosis: nonsmoker, normal CD4, undetectable
viral load, without dyslipidemia. Despite ART changes,
the patient developed bilateral osteonecrosis of the right
knee and of both humeral heads.
The second patient, male, 23 year-old with HIV-B3, was
treated in 2007 with AZT-3TC and lopinavir/ritonavir.
After 9 months of ART the patient had normal CD4
count and undetectable viral load but developed right
ANFH stage II, diagnosed by MRI, without surgery
recommendation. DXA didn’t show signs of osteoporosis
or osteopenia. The ART regimen was changed and the
patient received 3TC-ABC and raltegravir with good
ANFH outcome. After one year the patient discontinued
the ART. One year later symptoms related with avascular
osteonecrosis reappeared and bilateral ANFH was diag-
nosed by MRI. The patient had low CD4 count (<200/
cmm), high HIV viral load and positive antiphospholipid
antibodies. The patient had risk factors for coagulopathies:
smoker, recreational drug user, alcohol consumer, uncon-
trolled HIV infection with low CD4. We restarted the
same regimen with 3TC-ABC and raltegravir with a good
outcome for bone affliction. When HIV infection was
well-controlled, the antiphospholipid antibodies became
negative and bone affliction was improved.
We emphasize the importance of metabolic disturbances
in HIV-infected patients, among them avascular osteone-
crosis with different mechanisms. Both, ART and uncon-
trolled HIV infection can affect bone metabolism and
vascularization.
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